FDA Approval for Revolutionary Alzheimer’s Drug – Kisunla Clears Way for Breakthrough Treatment
Indianapolis, Indiana – The Food and Drug Administration gave the green light on Tuesday to a new Alzheimer’s treatment called donanemab, marking the third addition to a novel class of drugs designed to slow the brain’s decline in patients grappling with the early stages of the disease. Named Kisunla by Eli Lilly, the drug’s approval comes after facing numerous setbacks and delays in bringing the experimental treatment to the market, despite promising results from clinical …